IL1B and Parkinson disease: On a similar note, the blockade of the downstream cytokine signaling of NLRP3 by administering IL-1Ra, blocking the IL-1 receptor from binding IL-1β, resulted in decreased numbers of activated microglia in the SN, less DA neuronal loss and improved motor symptoms in the MPTP mouse model of PD [129].